Kukje Pharma Co., Ltd. (002720.KS)
KRW 4970.0
(-2.17%)
KRW 4970.0
(-2.17%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 21.24 Billion KRW | -4.46% |
| 2022 | 22.23 Billion KRW | 34.43% |
| 2021 | 16.54 Billion KRW | -23.61% |
| 2020 | 21.65 Billion KRW | 30.47% |
| 2019 | 16.59 Billion KRW | 17.0% |
| 2018 | 14.18 Billion KRW | -17.35% |
| 2017 | 17.16 Billion KRW | -3.95% |
| 2016 | 17.86 Billion KRW | -11.4% |
| 2015 | 20.16 Billion KRW | -19.77% |
| 2014 | 25.13 Billion KRW | 15.56% |
| 2013 | 21.75 Billion KRW | 20.23% |
| 2012 | 18.09 Billion KRW | 1.41% |
| 2011 | 17.84 Billion KRW | -25.18% |
| 2010 | 23.84 Billion KRW | -5.77% |
| 2009 | 25.3 Billion KRW | 7.05% |
| 2008 | 23.63 Billion KRW | 41.42% |
| 2007 | 16.71 Billion KRW | -9.92% |
| 2006 | 18.55 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 21.71 Billion KRW | 0.15% |
| 2024 Q1 | 21.68 Billion KRW | 2.09% |
| 2023 Q3 | 21.63 Billion KRW | 1.53% |
| 2023 Q4 | 21.24 Billion KRW | -1.83% |
| 2023 Q1 | 22.15 Billion KRW | -0.34% |
| 2023 Q2 | 21.31 Billion KRW | -3.81% |
| 2023 FY | 21.24 Billion KRW | -4.46% |
| 2022 Q1 | 18.27 Billion KRW | 10.46% |
| 2022 FY | 22.23 Billion KRW | 34.43% |
| 2022 Q4 | 22.23 Billion KRW | -1.81% |
| 2022 Q3 | 22.64 Billion KRW | 13.3% |
| 2022 Q2 | 19.98 Billion KRW | 9.4% |
| 2021 Q2 | 21.64 Billion KRW | -3.13% |
| 2021 Q1 | 22.34 Billion KRW | 3.21% |
| 2021 FY | 16.54 Billion KRW | -23.61% |
| 2021 Q4 | 16.54 Billion KRW | -20.58% |
| 2021 Q3 | 20.82 Billion KRW | -3.78% |
| 2020 Q1 | 18.63 Billion KRW | 12.29% |
| 2020 Q3 | 23.26 Billion KRW | 10.38% |
| 2020 Q4 | 21.65 Billion KRW | -6.95% |
| 2020 FY | 21.65 Billion KRW | 30.47% |
| 2020 Q2 | 21.07 Billion KRW | 13.11% |
| 2019 Q4 | 16.59 Billion KRW | -10.76% |
| 2019 FY | 16.59 Billion KRW | 17.0% |
| 2019 Q3 | 18.59 Billion KRW | -0.5% |
| 2019 Q2 | 18.68 Billion KRW | 5.52% |
| 2019 Q1 | 17.71 Billion KRW | 24.87% |
| 2018 Q4 | 14.18 Billion KRW | -6.22% |
| 2018 FY | 14.18 Billion KRW | -17.35% |
| 2018 Q1 | 15.74 Billion KRW | -8.28% |
| 2018 Q2 | 15.1 Billion KRW | -4.06% |
| 2018 Q3 | 15.12 Billion KRW | 0.16% |
| 2017 Q1 | 18.7 Billion KRW | 4.7% |
| 2017 FY | 17.16 Billion KRW | -3.95% |
| 2017 Q4 | 17.16 Billion KRW | -11.03% |
| 2017 Q3 | 19.29 Billion KRW | 6.23% |
| 2017 Q2 | 18.15 Billion KRW | -2.93% |
| 2016 Q3 | 18.41 Billion KRW | -9.99% |
| 2016 Q2 | 20.46 Billion KRW | 3.9% |
| 2016 Q1 | 19.69 Billion KRW | -2.34% |
| 2016 FY | 17.86 Billion KRW | -11.4% |
| 2016 Q4 | 17.86 Billion KRW | -2.99% |
| 2015 Q3 | 23.47 Billion KRW | 0.26% |
| 2015 Q2 | 23.41 Billion KRW | -10.31% |
| 2015 Q1 | 26.1 Billion KRW | 3.83% |
| 2015 FY | 20.16 Billion KRW | -19.77% |
| 2015 Q4 | 20.16 Billion KRW | -14.08% |
| 2014 Q3 | 23.44 Billion KRW | 2.75% |
| 2014 Q1 | 22.49 Billion KRW | 3.42% |
| 2014 Q4 | 25.13 Billion KRW | 7.21% |
| 2014 FY | 25.13 Billion KRW | 15.56% |
| 2014 Q2 | 22.81 Billion KRW | 1.44% |
| 2013 FY | 21.75 Billion KRW | 20.23% |
| 2013 Q2 | 19.62 Billion KRW | 5.51% |
| 2013 Q3 | 21.93 Billion KRW | 11.77% |
| 2013 Q4 | 21.75 Billion KRW | -0.83% |
| 2013 Q1 | 18.59 Billion KRW | 2.8% |
| 2012 Q1 | 19.87 Billion KRW | 0.0% |
| 2012 Q4 | 18.09 Billion KRW | 0.0% |
| 2012 FY | 18.09 Billion KRW | 1.41% |
| 2011 FY | 17.84 Billion KRW | -25.18% |
| 2011 Q1 | 23.84 Billion KRW | -13.05% |
| 2011 Q2 | 22.81 Billion KRW | -4.32% |
| 2011 Q3 | 19.39 Billion KRW | -14.99% |
| 2010 Q4 | 27.42 Billion KRW | -2.52% |
| 2010 FY | 23.84 Billion KRW | -5.77% |
| 2010 Q2 | 28.73 Billion KRW | 13.55% |
| 2010 Q3 | 28.13 Billion KRW | -2.09% |
| 2010 Q1 | 25.3 Billion KRW | -5.15% |
| 2009 FY | 25.3 Billion KRW | 7.05% |
| 2009 Q4 | 26.67 Billion KRW | 0.53% |
| 2009 Q3 | 26.53 Billion KRW | -0.34% |
| 2009 Q2 | 26.62 Billion KRW | 12.65% |
| 2009 Q1 | 23.63 Billion KRW | 2.91% |
| 2008 Q1 | 16.71 Billion KRW | -6.81% |
| 2008 Q2 | 19.25 Billion KRW | 15.2% |
| 2008 Q4 | 22.97 Billion KRW | 7.3% |
| 2008 Q3 | 21.4 Billion KRW | 11.18% |
| 2008 FY | 23.63 Billion KRW | 41.42% |
| 2007 Q2 | 18.63 Billion KRW | 0.0% |
| 2007 Q4 | 17.93 Billion KRW | -1.42% |
| 2007 FY | 16.71 Billion KRW | -9.92% |
| 2007 Q3 | 18.19 Billion KRW | -2.36% |
| 2006 FY | 18.55 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 51.887% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 81.975% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | 76.699% |
| HANDOK Inc. | 94.46 Billion KRW | 77.512% |
| Yuhan Corporation | 284.75 Billion KRW | 92.54% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 81.736% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -30.657% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 92.645% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | 34.403% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 65.584% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -9.067% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | 29.845% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | 56.061% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 51.887% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | 32.002% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | 39.61% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | 55.861% |
| JW Holdings Corporation | 147.58 Billion KRW | 85.607% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | 74.897% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 91.874% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 79.977% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 60.605% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | 21.316% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | 34.66% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | 80.647% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 51.887% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 88.739% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 91.205% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 79.977% |
| Yuhan Corporation | 284.75 Billion KRW | 92.54% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 83.044% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | 65.73% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 91.825% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 79.977% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | 73.314% |
| Korea United Pharm Inc. | 49.14 Billion KRW | 56.772% |
| CKD Bio Corp. | 69.08 Billion KRW | 69.25% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | 79.783% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | 69.952% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | 60.703% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 60.605% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 89.093% |
| Boryung Corporation | 189.8 Billion KRW | 88.808% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | 62.621% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 65.584% |
| JW Lifescience Corporation | 23.39 Billion KRW | 9.212% |